Trial Outcomes & Findings for PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus (NCT NCT04300296)
NCT ID: NCT04300296
Last Updated: 2023-08-22
Results Overview
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
111 participants
Primary outcome timeframe
Baseline up to week 16
Results posted on
2023-08-22
Participant Flow
163 subjects (3 cohorts) were screened and 111 were randomized. Subjects in the AIN457 300 mg Q4W group in TP1 continued on AIN457 300mg Q4W in TP2. Subjects in the Placebo group in TP1 received AIN457 300mg Q2W in TP2. Patients in the Placebo group with spontaneous remission at Week 16 entered the Follow-up period.
Participant milestones
| Measure |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort
AIN457 300 mg every 4 weeks administered via a pre-filled syringe. Participants on AIN457 in TP 1 for 16 weeks continued AIN457 in TP 2 for 16 weeks.
|
Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort
Placebo in TP1. Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort
AIN457 300 mg every 4 weeks administered via a pre-filled syringe. Participants on AIN457 in TP 1 for 16 weeks continued AIN457 in TP 2 for 16 weeks.
|
Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort
Placebo in TP1. Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort
AIN457 300 mg every 4 weeks administered via a pre-filled syringe. Participants on AIN457 in TP 1 for 16 weeks continued AIN457 in TP 2 for 16 weeks.
|
Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Placebo in TP1. Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Treatment Period 1: Baseline to 16 Weeks
NOT COMPLETED
|
2
|
2
|
0
|
0
|
1
|
1
|
|
Treatment Period 1: Baseline to 16 Weeks
STARTED
|
25
|
12
|
24
|
13
|
24
|
13
|
|
Treatment Period 1: Baseline to 16 Weeks
Placebo Responder
|
0
|
1
|
0
|
1
|
0
|
0
|
|
Treatment Period 1: Baseline to 16 Weeks
COMPLETED
|
23
|
10
|
24
|
13
|
23
|
12
|
|
Treatment Period 2: 16 to 32 Weeks
STARTED
|
22
|
8
|
23
|
11
|
23
|
12
|
|
Treatment Period 2: 16 to 32 Weeks
COMPLETED
|
17
|
7
|
19
|
10
|
17
|
12
|
|
Treatment Period 2: 16 to 32 Weeks
NOT COMPLETED
|
5
|
1
|
4
|
1
|
6
|
0
|
Reasons for withdrawal
| Measure |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort
AIN457 300 mg every 4 weeks administered via a pre-filled syringe. Participants on AIN457 in TP 1 for 16 weeks continued AIN457 in TP 2 for 16 weeks.
|
Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort
Placebo in TP1. Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort
AIN457 300 mg every 4 weeks administered via a pre-filled syringe. Participants on AIN457 in TP 1 for 16 weeks continued AIN457 in TP 2 for 16 weeks.
|
Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort
Placebo in TP1. Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort
AIN457 300 mg every 4 weeks administered via a pre-filled syringe. Participants on AIN457 in TP 1 for 16 weeks continued AIN457 in TP 2 for 16 weeks.
|
Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Placebo in TP1. Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Treatment Period 1: Baseline to 16 Weeks
Progressive disease
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period 1: Baseline to 16 Weeks
Adverse Event
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Treatment Period 1: Baseline to 16 Weeks
Subject/guardian decision
|
1
|
2
|
0
|
0
|
0
|
1
|
|
Treatment Period 2: 16 to 32 Weeks
Adverse Event
|
1
|
0
|
2
|
0
|
1
|
0
|
|
Treatment Period 2: 16 to 32 Weeks
Progressive disease
|
2
|
0
|
1
|
0
|
2
|
0
|
|
Treatment Period 2: 16 to 32 Weeks
Protocol deviation
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Treatment Period 2: 16 to 32 Weeks
Subject/guardian decision
|
2
|
0
|
1
|
1
|
3
|
0
|
Baseline Characteristics
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
Baseline characteristics by cohort
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
n=24 Participants
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Total
n=111 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|
|
Age, Customized
18 to <65 years
|
22 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
8 Participants
n=4 Participants
|
19 Participants
n=21 Participants
|
12 Participants
n=8 Participants
|
84 Participants
n=8 Participants
|
|
Age, Customized
> or = 65 years
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
27 Participants
n=8 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
20 Participants
n=21 Participants
|
10 Participants
n=8 Participants
|
79 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
32 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
Asian (Indian)
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
6 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
14 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
White
|
19 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
19 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
23 Participants
n=21 Participants
|
13 Participants
n=8 Participants
|
94 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
White, American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
|
Baseline of Investigator's Global Assessment (IGA)
0=Clear
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
|
Baseline of Investigator's Global Assessment (IGA)
1=Minimal
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
|
Baseline of Investigator's Global Assessment (IGA)
2=Mild
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
|
Baseline of Investigator's Global Assessment (IGA)
3=Moderate
|
16 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
22 Participants
n=5 Participants
|
8 Participants
n=4 Participants
|
17 Participants
n=21 Participants
|
10 Participants
n=8 Participants
|
82 Participants
n=8 Participants
|
|
Baseline of Investigator's Global Assessment (IGA)
4=Severe
|
8 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
7 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
28 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Baseline up to week 16Population: Full analysis set of participants with a baseline IGA score \>= 3 were included
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
n=24 Participants
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP
|
44.0 percentage of participants
Interval 25.8 to 63.32
|
58.2 percentage of participants
Interval 31.0 to 82.6
|
37.5 percentage of participants
Interval 20.3 to 57.2
|
23.1 percentage of participants
Interval 6.5 to 49.2
|
37.6 percentage of participants
Interval 20.2 to 57.3
|
30.9 percentage of participants
Interval 10.8 to 57.6
|
SECONDARY outcome
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA <=2 n=25,12,0
|
5 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA 0/1 n=25,12,0
|
4 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA 0/1 n=25,0,10
|
10 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA improvement >=2 n=25,12,0
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA 0/1 n=25,12,0
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA <=2 n=24,11,0
|
9 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA improvement. >=2 n=24,11,0
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA 0/1 n=24,11,0
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA <=2 n=25,11,0
|
10 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA improvement. >=2 n=25,11,0
|
4 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA 0/1 n=25,11,0
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA <=2 n=25,12,0
|
10 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA improvement. >=2 n=25,12,0
|
3 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week16 IGA <=2 n=25,12,10
|
11 Participants
|
7 Participants
|
5 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 16 IGA improvement. >=2 n=25,12,10
|
4 Participants
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 16 IGA 0/1 n=25,12,10
|
4 Participants
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA <=2 n=24,0,10
|
11 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA improvement. >=2 n=24,0,10
|
5 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA 0/1 n=24,0,10
|
5 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA <=2 n=25,0,10
|
14 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA improvement. >=2 n=25,0,10
|
10 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA <=2 n=23,0,10
|
12 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA improvement. >=2 n=23,0,10
|
7 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA 0/1 n=23,0,10
|
6 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA <=2 n=24,0,9
|
9 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA improvement. >=2 n=24,0,9
|
7 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA 0/1 n=24,0,9
|
6 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=11 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA <=2 n=23,0,10
|
9 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA improvement. >=2 n=23,0,10
|
2 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA 0/1 n=24,0,10
|
3 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA <=2 n=23,0,11
|
7 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA improvement. >=2 n=23,0,11
|
1 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA 0/1 n=23,0,11
|
1 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA 0/1 n=23,0,10
|
2 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA <=2 n=24,12,0
|
5 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA improvement >=2 n=24,12,0
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA 0/1 n=24,12,0
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA <=2 n=24,13,0
|
4 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA improvement. >=2 n=24,13,0
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA 0/1 n=24,13,0
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA <=2 n=24,13,0
|
5 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA improvement. >=2 n=24,13,0
|
0 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA 0/1 n=24,13,0
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA <=2 n=24,13,0
|
5 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA improvement. >=2 n=24,13,0
|
5 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA 0/1 n=24,13,0
|
4 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week16 IGA <=2 n=24,13,11
|
9 Participants
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 16 IGA improvement. >=2 n=24,13,11
|
5 Participants
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 16 IGA 0/1 n=24,13,11
|
4 Participants
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA <=2 n=24,0,11
|
10 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA improvement. >=2 n=24,0,11
|
5 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA 0/1 n=24,0,11
|
5 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA <=2 n=24,0,10
|
10 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA improvement. >=2 n=24,0,10
|
3 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=13 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA improvement. >=2 n=24,13,0
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA 0/1 n=24,0,13
|
5 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA improvement. >=2 n==24,0,11
|
5 Participants
|
—
|
5 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA 0/1 n=24,13,0
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA <=2 n=24,13,0
|
9 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA improvement. >=2 n=24,13,0
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 4 IGA 0/1 n=24,13,0
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA <=2 n=24,13,0
|
8 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 8 IGA 0/1 n=24,13,0
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA <=2 n=24,13,0
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA <=2 n=24,13,0
|
4 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 2 IGA improvement >=2 n=24,13,0
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA improvement. >=2 n=24,13,0
|
3 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 12 IGA 0/1 n=24,13,0
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week16 IGA <=2 n=24,13,13
|
9 Participants
|
4 Participants
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 16 IGA improvement. >=2 n=24,13,13
|
3 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 16 IGA 0/1 n=24,13,13
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA <=2 n=24,0,13
|
10 Participants
|
—
|
6 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA improvement. >=2 n=24,0,13
|
6 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 20 IGA 0/1 n=24,0,13
|
4 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA <=2 n=23,0,13
|
10 Participants
|
—
|
8 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA improvement. >=2 n=23,0,13
|
7 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 24 IGA 0/1 n=23,0,13
|
6 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA <=2 n=24,0,13
|
10 Participants
|
—
|
9 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 28 IGA improvement. >=2 n=24,0,13
|
6 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA <=2 n==24,0,11
|
11 Participants
|
—
|
7 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Week 32 IGA 0/1 n==24,0,11
|
4 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=\<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=\>50% of total body surface
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Baseline 0 Score
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Baseline 1 score
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Baseline 3 score
|
6 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Baseline 4 score
|
5 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 2 3 score
|
9 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 8 3 score
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 12 4 score
|
3 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 20 2 score
|
12 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 20 4 score
|
1 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 20 5 score
|
2 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 24 0 score
|
1 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 24 1 score
|
8 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 24 2 score
|
10 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 24 3 score
|
1 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 24 4 score
|
2 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 24 5 score
|
3 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 28 0 score
|
0 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 28 3 score
|
1 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 28 4 score
|
3 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 32 2 score
|
10 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 32 3 score
|
3 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 32 4 score
|
1 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 32 5 score
|
3 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Baseline 2 score
|
6 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Baseline 5 score
|
5 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 2 0 score
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 2 1 score
|
6 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 2 2 score
|
5 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 2 4 score
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 2 5 score
|
2 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 4 0 score
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 4 1 score
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 4 2 score
|
8 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 4 3 score
|
8 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 4 4 score
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 4 5 score
|
2 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 8 0 score
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 8 1 score
|
7 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 8 2 score
|
5 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 8 4 score
|
4 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 8 5 score
|
2 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 12 0 score
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 12 1 score
|
6 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 12 2 score
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 12 3 score
|
7 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 12 5 score
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 16 0 score
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 16 1 score
|
4 Participants
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 16 2 score
|
12 Participants
|
3 Participants
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 16 3 score
|
5 Participants
|
3 Participants
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 16 4 score
|
2 Participants
|
4 Participants
|
4 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 16 5 score
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 20 0 score
|
0 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 20 1 score
|
6 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 20 3 score
|
3 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 28 1 score
|
6 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 28 2 score
|
11 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 28 5 score
|
2 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 32 0 score
|
2 Participants
|
—
|
0 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
Week 32 1 score
|
5 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Baseline n=25,12,0
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 4 n=24,11,0
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 8 n=25,11,0
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 12 n=25,12,0
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 16 n=25,12,10
|
3 Participants
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 20 n=24,0,10
|
3 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 24 n=25,0,10
|
4 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 28 n=23,0,10
|
3 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
Week 32 n=25,0,9
|
2 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=11 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Baseline n=24,13,0
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 4 n=24,13,0
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 8 n=24,13,0
|
4 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 12 n=24,13,0
|
4 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 16 n=24,13,11
|
5 Participants
|
3 Participants
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 20 n=24,0,11
|
7 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 24 n=24,0,10
|
7 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 28 n=23,0,11
|
3 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
Week 32 n=23,0,10
|
4 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=13 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Baseline n=24,13,0
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 4 n=24,13,0
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 8 n=24,13,0
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 12 n=24,13,0
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 16 n=24,13,13
|
2 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 20 n=24,0,13
|
4 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 24 n=23,0,13
|
2 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 28 n=24,0,13
|
2 Participants
|
—
|
2 Participants
|
—
|
—
|
—
|
|
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
Week 32 n=24,0,11
|
1 Participants
|
—
|
3 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Baseline - Question 1
|
5.1 scores on a scale
Standard Deviation 2.66
|
5.7 scores on a scale
Standard Deviation 2.77
|
5.8 scores on a scale
Standard Deviation 3.01
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 16 Severity of itch during past 24 hours n=25,12,10
|
-0.8 scores on a scale
Standard Deviation 1.91
|
-2.3 scores on a scale
Standard Deviation 3.25
|
-2.0 scores on a scale
Standard Deviation 3.53
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 32 Severity of itch during past 24 hours n=25,0,9
|
-1.5 scores on a scale
Standard Deviation 2.24
|
—
|
-1.1 scores on a scale
Standard Deviation 2.42
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Baseline- Question 2
|
5.6 scores on a scale
Standard Deviation 2.72
|
6.3 scores on a scale
Standard Deviation 2.86
|
5.9 scores on a scale
Standard Deviation 3.03
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10
|
-0.9 scores on a scale
Standard Deviation 2.52
|
-2.7 scores on a scale
Standard Deviation 3.73
|
-1.9 scores on a scale
Standard Deviation 3.54
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9
|
-1.3 scores on a scale
Standard Deviation 2.13
|
—
|
-1.2 scores on a scale
Standard Deviation 2.49
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Baseline- Question 3
|
4.8 scores on a scale
Standard Deviation 3.08
|
6.1 scores on a scale
Standard Deviation 2.94
|
6.1 scores on a scale
Standard Deviation 3.21
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 16 How bothered by Itch during past 24 hours n=25,12,10
|
-1.0 scores on a scale
Standard Deviation 2.65
|
-2.7 scores on a scale
Standard Deviation 3.55
|
-2.4 scores on a scale
Standard Deviation 3.84
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 32 How bothered by Itch during past 24 hours n=25,0,9
|
-1.1 scores on a scale
Standard Deviation 2.45
|
—
|
-1.2 scores on a scale
Standard Deviation 2.28
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=11 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Baseline - Question 1 n=23,13,11
|
2.5 scores on a scale
Standard Deviation 2.83
|
3.8 scores on a scale
Standard Deviation 3.81
|
4.3 scores on a scale
Standard Deviation 3.93
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Week 16 Severity of itch during past 24 hours n=23,13,11
|
0.3 scores on a scale
Standard Deviation 3.26
|
-0.2 scores on a scale
Standard Deviation 3.41
|
-0.3 scores on a scale
Standard Deviation 3.72
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Week 32 Severity of itch during past 24 hours n=22,0,10
|
0.1 scores on a scale
Standard Deviation 2.97
|
—
|
-0.4 scores on a scale
Standard Deviation 3.37
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Baseline - Question 2 n=23,13,11
|
2.4 scores on a scale
Standard Deviation 2.90
|
3.6 scores on a scale
Standard Deviation 3.99
|
4.1 scores on a scale
Standard Deviation 4.16
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11
|
0.8 scores on a scale
Standard Deviation 3.04
|
0.4 scores on a scale
Standard Deviation 3.25
|
0.4 scores on a scale
Standard Deviation 3.56
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Week 32 How severe was itch at worst moment during past 24 hours n=22,0,10
|
0.3 scores on a scale
Standard Deviation 2.43
|
—
|
0.4 scores on a scale
Standard Deviation 3.81
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Baseline - Question 3 n=24,13,11
|
3.4 scores on a scale
Standard Deviation 3.41
|
4.0 scores on a scale
Standard Deviation 4.14
|
4.5 scores on a scale
Standard Deviation 4.27
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Week 16 How bothered by Itch during past 24 hours n=23,13,11
|
-0.5 scores on a scale
Standard Deviation 2.95
|
0.1 scores on a scale
Standard Deviation 3.12
|
0.0 scores on a scale
Standard Deviation 3.41
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Week 32 How bothered by Itch during past 24 hours n=22,0,10
|
-0.2 scores on a scale
Standard Deviation 1.33
|
—
|
-0.4 scores on a scale
Standard Deviation 4.25
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=13 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Baseline - Question 3 n=24,13,11
|
4.0 scores on a scale
Standard Deviation 2.36
|
3.2 scores on a scale
Standard Deviation 2.79
|
3.2 scores on a scale
Standard Deviation 2.79
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 16 How bothered by Itch during past 24 hours n=24,13,13
|
-0.4 scores on a scale
Standard Deviation 2.43
|
-1.2 scores on a scale
Standard Deviation 3.02
|
-1.2 scores on a scale
Standard Deviation 3.02
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 32 How bothered by Itch during past 24 hours n=24,0,11
|
-1.7 scores on a scale
Standard Deviation 2.08
|
—
|
-2.2 scores on a scale
Standard Deviation 2.44
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Baseline - Question 1 n=24,13,13
|
4.5 scores on a scale
Standard Deviation 2.25
|
3.8 scores on a scale
Standard Deviation 2.68
|
3.8 scores on a scale
Standard Deviation 2.68
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 16 Severity of itch during past 24 hours n=24,13,11
|
-0.5 scores on a scale
Standard Deviation 2.25
|
-1.1 scores on a scale
Standard Deviation 2.47
|
-1.1 scores on a scale
Standard Deviation 2.47
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 32 Severity of itch during past 24 hours n=24,0,11
|
-1.6 scores on a scale
Standard Deviation 2.06
|
—
|
-2.4 scores on a scale
Standard Deviation 2.84
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Baseline - Question 2 n=24,13,13
|
5.1 scores on a scale
Standard Deviation 2.43
|
4.2 scores on a scale
Standard Deviation 2.86
|
4.1 scores on a scale
Standard Deviation 4.16
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13
|
-0.7 scores on a scale
Standard Deviation 2.35
|
-1.3 scores on a scale
Standard Deviation 2.81
|
-1.3 scores on a scale
Standard Deviation 2.81
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11
|
-1.8 scores on a scale
Standard Deviation 2.23
|
—
|
-2.6 scores on a scale
Standard Deviation 3.01
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=25 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Baseline - Question 1 n=25,12,10
|
1.09 scores on a scale
Standard Deviation 2.05
|
3.4 scores on a scale
Standard Deviation 2.61
|
3.5 scores on a scale
Standard Deviation 2.51
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 16 Severity of pain during past 24 hours n=25,12,10
|
0.2 scores on a scale
Standard Deviation 1.48
|
-0.8 scores on a scale
Standard Deviation 1.40
|
-0.8 scores on a scale
Standard Deviation 1.48
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 32 Severity of pain during past 24 hours n=25,0,9
|
-0.3 scores on a scale
Standard Deviation 1.65
|
—
|
-0.3 scores on a scale
Standard Deviation 2.29
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Baseline - Question 2 n=25,12,10
|
2.2 scores on a scale
Standard Deviation 2.48
|
3.9 scores on a scale
Standard Deviation 3.23
|
3.9 scores on a scale
Standard Deviation 3.03
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10
|
0.1 scores on a scale
Standard Deviation 2.03
|
-1.2 scores on a scale
Standard Deviation 1.70
|
-1.0 scores on a scale
Standard Deviation 1.56
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9
|
-0.4 scores on a scale
Standard Deviation 2.35
|
—
|
-0.4 scores on a scale
Standard Deviation 2.70
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Baseline - Question 3 n=25,12,10
|
2.1 scores on a scale
Standard Deviation 2.55
|
3.7 scores on a scale
Standard Deviation 2.96
|
3.8 scores on a scale
Standard Deviation 2.94
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 16 How bothered by pain during past 24 hour n=25,12,10
|
0.1 scores on a scale
Standard Deviation 2.09
|
-0.6 scores on a scale
Standard Deviation 1.62
|
0.5 scores on a scale
Standard Deviation 1.72
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Week 32 How bothered by pain during past 24 hours n=25, 0,9
|
-0.2 scores on a scale
Standard Deviation 1.71
|
—
|
-0.3 scores on a scale
Standard Deviation 2.45
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=11 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Baseline - Question 1 n=24,13,11
|
5.1 scores on a scale
Standard Deviation 2.86
|
5.9 scores on a scale
Standard Deviation 3.09
|
6.3 scores on a scale
Standard Deviation 3.23
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Week 16 Severity of pain during past 24 hours n=24,13,11
|
-0.5 scores on a scale
Standard Deviation 3.08
|
-0.1 scores on a scale
Standard Deviation 3.01
|
0.0 scores on a scale
Standard Deviation 3.29
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Week 32 Severity of pain during past 24 hours n=23,0,10
|
-0.3 scores on a scale
Standard Deviation 2.18
|
—
|
-0.6 scores on a scale
Standard Deviation 2.59
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Baseline - Question 2 n=24,13,11
|
5.4 scores on a scale
Standard Deviation 2.99
|
6.4 scores on a scale
Standard Deviation 3.15
|
6.7 scores on a scale
Standard Deviation 3.26
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11
|
-0.5 scores on a scale
Standard Deviation 3.13
|
-0.3 scores on a scale
Standard Deviation 2.75
|
-0.2 scores on a scale
Standard Deviation 2.99
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10
|
-0.3 scores on a scale
Standard Deviation 2.06
|
—
|
-0.5 scores on a scale
Standard Deviation 2.46
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Baseline - Question 3 n=24,13,11
|
5.5 scores on a scale
Standard Deviation 3.35
|
6.5 scores on a scale
Standard Deviation 2.76
|
6.8 scores on a scale
Standard Deviation 2.79
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Week 16 How bothered by pain during past 24 hour n=24,13,11
|
-0.8 scores on a scale
Standard Deviation 3.54
|
-0.3 scores on a scale
Standard Deviation 2.21
|
-0.1 scores on a scale
Standard Deviation 2.34
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Week 32 How bothered by pain during past 24 hours n=23,0,10
|
-0.5 scores on a scale
Standard Deviation 2.74
|
—
|
-0.9 scores on a scale
Standard Deviation 2.69
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=12 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Baseline - Question 1 n=24,13,12
|
2.5 scores on a scale
Standard Deviation 2.43
|
2.0 scores on a scale
Standard Deviation 2.38
|
2.0 scores on a scale
Standard Deviation 2.38
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 16 Severity of pain during past 24 hours n=24,13,12
|
0.3 scores on a scale
Standard Deviation 2.61
|
-0.5 scores on a scale
Standard Deviation 1.90
|
-0.5 scores on a scale
Standard Deviation 1.90
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 32 Severity of pain during past 24 hours n=24,0,11
|
-0.6 scores on a scale
Standard Deviation 1.72
|
—
|
-1.5 scores on a scale
Standard Deviation 2.02
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Baseline - Question 2 24,13,12
|
2.8 scores on a scale
Standard Deviation 2.68
|
2.5 scores on a scale
Standard Deviation 2.73
|
2.5 scores on a scale
Standard Deviation 2.73
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12
|
0.2 scores on a scale
Standard Deviation 3.16
|
-0.9 scores on a scale
Standard Deviation 2.25
|
-0.9 scores on a scale
Standard Deviation 2.25
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11
|
-0.8 scores on a scale
Standard Deviation 2.06
|
—
|
-2.0 scores on a scale
Standard Deviation 2.45
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Baseline - Question 3 n=24,13,12
|
2.7 scores on a scale
Standard Deviation 2.56
|
2.4 scores on a scale
Standard Deviation 2.75
|
2.4 scores on a scale
Standard Deviation 2.75
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 16 How bothered by pain during past 24 hour n=24,13,12
|
0.0 scores on a scale
Standard Deviation 2.87
|
-1.1 scores on a scale
Standard Deviation 2.25
|
-1.1 scores on a scale
Standard Deviation 2.25
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Week 32 How bothered by pain during past 24 hours n=24,0,11
|
-0.8 scores on a scale
Standard Deviation 1.79
|
—
|
-1.9 scores on a scale
Standard Deviation 2.51
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=21 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period
Baseline n=21,12,10
|
21.31 scores on a scale
Standard Deviation 8.747
|
25.29 scores on a scale
Standard Deviation 9.102
|
26.95 scores on a scale
Standard Deviation 8.855
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period
Week 16 n=21,12,10
|
-4.83 scores on a scale
Standard Deviation 11.102
|
-5.79 scores on a scale
Standard Deviation 14.476
|
-4.10 scores on a scale
Standard Deviation 15.196
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period
Week 32 n=20,0,9
|
-6.08 scores on a scale
Standard Deviation 10.206
|
—
|
-2.17 scores on a scale
Standard Deviation 15.802
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=21 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=12 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=10 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period
Baseline n=21,12,10
|
11.0 scores on a scale
Standard Deviation 5.98
|
13.4 scores on a scale
Standard Deviation 5.50
|
13.9 scores on a scale
Standard Deviation 5.78
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period
Week 16 n=21,12,10
|
-1.0 scores on a scale
Standard Deviation 6.82
|
0.8 scores on a scale
Standard Deviation 6.47
|
-0.4 scores on a scale
Standard Deviation 7.09
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period
Week 32 n=20,0,9
|
-1.8 scores on a scale
Standard Deviation 5.67
|
—
|
-0.7 scores on a scale
Standard Deviation 7.00
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=13 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)
Week 16 n=24,13,13
|
-1.44 scores on a scale
Standard Deviation 2.517
|
-2.24 scores on a scale
Standard Deviation 2.522
|
-2.24 scores on a scale
Standard Deviation 2.522
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)
Week 32 n=24,0,13
|
-2.44 scores on a scale
Standard Deviation 2.428
|
—
|
-3.20 scores on a scale
Standard Deviation 2.927
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)
Baseline n=24,13,13
|
5.92 scores on a scale
Standard Deviation 2.071
|
5.95 scores on a scale
Standard Deviation 1.767
|
5.95 scores on a scale
Standard Deviation 1.767
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 16 and Week 32Population: Full analysis set. Patients who were included in FAS for TP1 were included in FAS for TP2 except that the placebo patients in spontaneous remission at Week 16 were excluded from Placebo- AIN457 300 mg Q2W TP2 group. Patients who discontinued study treatment before week 32 were imputed using baseline observation carried forward. Missing values not related to treatment discontinuation were analyzed as observed.
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life.
Outcome measures
| Measure |
AIN457 300 mg Q4W - TP 1 - CLP Cohort
n=24 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - CLP Cohort
n=13 Participants
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - MLP Cohort
n=12 Participants
AIN457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - MLP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
AIN457 300 mg Q4W - TP 1 - LPP Cohort
AIN457457 300 mg every 4 weeks up to 16 weeks administered via a pre-filled syringe
|
Placebo - TP 1 - LPP Cohort
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
|---|---|---|---|---|---|---|
|
Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)
Baseline n=24,13,12
|
55.75 scores on a scale
Standard Deviation 16.476
|
54.01 scores on a scale
Standard Deviation 23.252
|
54.01 scores on a scale
Standard Deviation 23.252
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)
Week 16 n=24,13,12
|
1.86 scores on a scale
Standard Deviation 10.695
|
-6.94 scores on a scale
Standard Deviation 11.508
|
-6.94 scores on a scale
Standard Deviation 11.508
|
—
|
—
|
—
|
|
Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)
Week 32 n=24,0,11
|
-4.26 scores on a scale
Standard Deviation 12.876
|
—
|
-14.43 scores on a scale
Standard Deviation 16.464
|
—
|
—
|
—
|
Adverse Events
AIN457 300 mg Q4W - CLP Cohort
Serious events: 0 serious events
Other events: 15 other events
Deaths: 0 deaths
Placebo - CLP Cohort
Serious events: 1 serious events
Other events: 7 other events
Deaths: 0 deaths
Any AIN457 300 mg - CLP Cohort
Serious events: 0 serious events
Other events: 21 other events
Deaths: 0 deaths
Placebo to AIN457 300 mg Q2W - CLP Cohort
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
AIN457 300 mg Q4W - MLP Cohort
Serious events: 1 serious events
Other events: 18 other events
Deaths: 0 deaths
Placebo - MLP Cohort
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Any AIN457 300 mg - MLP Cohort
Serious events: 2 serious events
Other events: 26 other events
Deaths: 0 deaths
Placebo to AIN457 300 mg Q2W - MLP Cohort
Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths
AIN457 300 mg Q4W - LPP Cohort
Serious events: 0 serious events
Other events: 16 other events
Deaths: 0 deaths
Placebo - LPP Cohort
Serious events: 1 serious events
Other events: 7 other events
Deaths: 0 deaths
Any AIN457 300 mg - LPP Cohort
Serious events: 1 serious events
Other events: 22 other events
Deaths: 0 deaths
Placebo to AIN457 300 mg Q2W - LPP Cohort
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
AIN457 300 mg Q4W - CLP Cohort
n=25 participants at risk
AIN457 300 mg every 4 weeks up to 32 weeks administered via a pre-filled syringe
|
Placebo - CLP Cohort
n=12 participants at risk
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Any AIN457 300 mg - CLP Cohort
n=33 participants at risk
AIN457 300mg administered every 4 weeks or every 2 weeks via a pre-filled syringe
|
Placebo to AIN457 300 mg Q2W - CLP Cohort
n=8 participants at risk
Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe.
|
AIN457 300 mg Q4W - MLP Cohort
n=24 participants at risk
AIN457 300 mg every 4 weeks up to 32 weeks administered via a pre-filled syringe
|
Placebo - MLP Cohort
n=13 participants at risk
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Any AIN457 300 mg - MLP Cohort
n=35 participants at risk
AIN457 300mg administered every 4 weeks or every 2 weeks via a pre-filled syringe
|
Placebo to AIN457 300 mg Q2W - MLP Cohort
n=11 participants at risk
Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe.
|
AIN457 300 mg Q4W - LPP Cohort
n=24 participants at risk
AIN457457 300 mg every 4 weeks up to 32 weeks administered via a pre-filled syringe
|
Placebo - LPP Cohort
n=13 participants at risk
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Any AIN457 300 mg - LPP Cohort
n=36 participants at risk
AIN457 300mg administered every 4 weeks or every 2 weeks via a pre-filled syringe
|
Placebo to AIN457 300 mg Q2W - LPP Cohort
n=12 participants at risk
Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
Other adverse events
| Measure |
AIN457 300 mg Q4W - CLP Cohort
n=25 participants at risk
AIN457 300 mg every 4 weeks up to 32 weeks administered via a pre-filled syringe
|
Placebo - CLP Cohort
n=12 participants at risk
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Any AIN457 300 mg - CLP Cohort
n=33 participants at risk
AIN457 300mg administered every 4 weeks or every 2 weeks via a pre-filled syringe
|
Placebo to AIN457 300 mg Q2W - CLP Cohort
n=8 participants at risk
Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe.
|
AIN457 300 mg Q4W - MLP Cohort
n=24 participants at risk
AIN457 300 mg every 4 weeks up to 32 weeks administered via a pre-filled syringe
|
Placebo - MLP Cohort
n=13 participants at risk
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Any AIN457 300 mg - MLP Cohort
n=35 participants at risk
AIN457 300mg administered every 4 weeks or every 2 weeks via a pre-filled syringe
|
Placebo to AIN457 300 mg Q2W - MLP Cohort
n=11 participants at risk
Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe.
|
AIN457 300 mg Q4W - LPP Cohort
n=24 participants at risk
AIN457457 300 mg every 4 weeks up to 32 weeks administered via a pre-filled syringe
|
Placebo - LPP Cohort
n=13 participants at risk
Matching placebo administered every 4 weeks up to 16 weeks via a pre-filled syringe
|
Any AIN457 300 mg - LPP Cohort
n=36 participants at risk
AIN457 300mg administered every 4 weeks or every 2 weeks via a pre-filled syringe
|
Placebo to AIN457 300 mg Q2W - LPP Cohort
n=12 participants at risk
Placebo non-responders during TP 1 received AIN457 300 mg every 2 weeks from Week 16 to Week 32 in TP 2 via a pre-filled syringe.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Ear and labyrinth disorders
Auricular swelling
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Eye disorders
Dry eye
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
18.2%
2/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Diarrhoea
|
8.0%
2/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
3/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.6%
3/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
18.2%
2/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Haemorrhoids
|
8.0%
2/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
6.1%
2/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Leukoplakia oral
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
General disorders
Asthenia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
General disorders
Fatigue
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
General disorders
Injection site haemorrhage
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
General disorders
Oedema peripheral
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
General disorders
Peripheral swelling
|
8.0%
2/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
6.1%
2/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
General disorders
Pyrexia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Immune system disorders
Immunisation reaction
|
12.0%
3/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
3/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
COVID-19
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
6.1%
2/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
11.4%
4/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
18.2%
2/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Cystitis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Ear infection
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Furuncle
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Herpes ophthalmic
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Nasopharyngitis
|
8.0%
2/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
6.1%
2/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Oral candidiasis
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
3/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Oral herpes
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Post-acute COVID-19 syndrome
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Sinusitis
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Superinfection
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Tongue fungal infection
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Infections and infestations
Urinary tract infection
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Injury, poisoning and procedural complications
Traumatic fracture
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Investigations
SARS-CoV-2 test positive
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
3/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
3/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Exostosis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis of jaw
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Nervous system disorders
Dizziness
|
4.0%
1/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Nervous system disorders
Headache
|
12.0%
3/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
3/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.7%
2/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
18.2%
2/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
20.8%
5/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
15.4%
2/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
13.9%
5/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Nervous system disorders
Syncope
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Renal and urinary disorders
Micturition disorder
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Reproductive system and breast disorders
Breast cyst
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
3.0%
1/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Intertrigo
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.8%
1/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Lichen planus
|
12.0%
3/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.1%
4/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
1/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
16.7%
4/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
14.3%
5/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
3/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.6%
3/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
12.5%
3/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
3/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Skin burning sensation
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
2/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
|
Vascular disorders
Hypertension
|
8.0%
2/25 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
6.1%
2/33 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/8 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
7.7%
1/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
2.9%
1/35 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
4.2%
1/24 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
15.4%
2/13 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
5.6%
2/36 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
8.3%
1/12 • Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.
"Any AIN457 300 mg Q4W" Arm/Group Total Number at Risk represents all participants who were assigned AIN457 300 mg Q4W for a given cohort during the study. Participants who were on placebo in Treatment Period 1 who continued into Treatment Period 2 received AIN457 300 mg Q2W.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
- Publication restrictions are in place
Restriction type: OTHER